The results of a joint study between Rosetta Genomics and NYUs Langone Medical Center indicate promising results in therapies to combat mesothelioma and other cancers.
The study, “Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma,” shows the potential of miR-31 – a micro RNA recently discovered to be a suppressor of breast cancer metastases – to inhibit proliferation, migration, invasion and clonogenicity of mesothelioma cells. Cell lines from mesothelioma patients were found not to express the microRNA.
“Over the past several years, microRNAs have been hailed as one of the most significant scientific and medical discoveries. They have been described as the body’s ‘master switches’, holding significant potential for therapeutic applications,” said Kenneth A. Berlin, President and CEO of Rosetta Genomics.
Berlin also noted how the study is yet another demonstration of microRNAs potential role in cancer therapeutics and how significant an impact a single microRNA can have on the course of a disease. MicroRNAs (miRNAs) are recently discovered, small RNAs that play the “master regulator” of protein synthesis, and are highly effective biomarkers. Early data has shown that cancer cell growth may be reduced by controlling levels of specific microRNAs.
Founded in 2000, Rosetta Genomics is a company on the forefront of microRNA-based molecular diagnostics and was the winner of the Wall Street Journal’s Technology Innovation Awards in the medical/biotech category.